Risk factor
Strong trading liquidity
Profitability factor
Somewhat favourable analyst view
About
Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Its reach extends across Japan, the Americas, the Middle East, Asia, and Oceania. The company structures its operations around three primary divisions: Endoscopic Solutions, Therapeutic Solutions, and Other business segments. Its extensive product portfolio includes advanced gastrointestinal endoscopy systems, incorporating video and ultrasound technologies, as well as GI endotherapy tools for treating colorectal conditions, HPB (hepatopancreatobiliary) issues, and hemostasis. Olympus also delivers comprehensive endoscopic ecosystem solutions, which feature intelligent operating software platforms, AI-driven insights, and computer-aided detection and diagnosis functionalities. Furthermore, it provides reprocessing solutions for endoscopes, including reprocessors, chemicals, and related accessories, supported by essential medical services such as repair center operations. The company also supplies respiratory care devices, offering bronchoscopy systems and solutions for lung cancer and chronic obstructive pulmonary disease. Its urology offerings encompass visualization tools, stone management, and treatments for benign prostatic hyperplasia (BPH) and BPH with bladder cancer. Within its surgical segment, Olympus features surgical endoscopy systems, cutting-edge energy devices, surgical microscopes, integrated operating room solutions, rhino-laryngoscopy systems, and instruments tailored for ear, nose, and throat surgeries. Various gastroenterology and gynecology devices further round out its product offerings. Established in 1919, the company was initially known as Olympus Optical Co., Ltd., before officially changing its name to Olympus Corporation in October 2003. Its global headquarters are situated in Hachioji, Japan.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, o
Target Price
The average target price of 7733.T is 1853 and suggests 9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation